Risankizumab induces deep remissions in Crohn’s disease trial
Phase III trial data shows more than half of patients…
Phase III trial data shows more than half of patients with moderate to severe Crohn's disease treated with risankizumab (Skyrizi®) 360mg achieved clinical remission in a year.